Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
US9771371B2 · kind B2 · utility
4Cited by
15References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 5, 2015 |
| Grant date | Sep 26, 2017 |
| Priority date | — |
| Expiry date | Oct 5, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are Heteroaryl Compounds having the following structure:wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.